Therapeutic renin-angiotensin vaccines for the treatment of hypertension

Drugs of the Future

Volumn 33, Issue 12, 2008, Pages 1041-1049

  Zhu, Feng ^a   Liao, Yu Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; CYT 006 ANGQB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPITOPE; HYPERTENSION VACCINE; PMD 3117; RENIN INHIBITOR; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; VIRUS LIKE AGENT;

EID: 62649118757     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.33.12.1287736     Document Type: Review

References (85)

1. Elkind, M.S., Sacco, R.L. Stroke risk factors and stroke prevention. Semin Neurol 1998, 18(4): 429-40.
2. Hall, W.D. Risk reduction associated with lowering systolic blood pressure: Review of clinical trial data. Am Heart J 1999, 138(3, Pt. 2): 225-30.
3. Chobanian, A.V., Bakris, G.L., Black, H.R. et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003, 289(19): 2560-72.
4. Liu, L. The study of hypertension in China. Blood Press 2004, 13(2): 72-4.
5. Tigerstedt, R., Bergman, P.G, Niere und Kreislauf. Scand Arch Physiol 1898, 8: 223-71.
6. de Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W., Unger, T.H. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000, 52(3): 415-72.
7. 1 receptor antagonist. J Biol Chem 2001, 276(43): 39721-6.
8. Haulica, I., Bild, W., Serban, D.N. Angiotensin peptides and their pleiotropic actions. J Renin Angotensin Aldosterone Syst 2005, 6(3): 121-31.
9. Michel, J.B., Guettier, C., Philippe, M., Galen, F.X., Corvol, P., Ménard, J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci USA 1987, 84(12): 4346-50.
10. Michel, J.B., Sayah, S., Guettier, C. et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990, 81(6): 1899-910.
11. Staessen, J.A., Li, Y., Richart, T. Oral renin inhibitors. Lancet 2006, 368(9545): 1449-56.
12. Brown, M.J., Coltart, J., Gunewardena, K., Ritter, J.M., Auton, T.R., Glover, J.F. Randomized double-blind placebo-controlled study of an angiotensin iminunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107(2): 167-73.
13. Ambühl, P.M., Tissot, A C., Fulurija, A. et al. A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25(1): 63-72.
14. Oates, H.F., Stokes, G.S. Plasma renin activity of rats and rabbits immunized against angiotensin II. Clin Exp Pharmacol Physiol 1974, 1(2): 161-6.
15. Stokes, G.S., Oates, H.F., Weber, M.A. Angiotensin blockade in studies of the feedback control of renin release in rats and rabbits. Clin Sci Mol Med Suppl 1975, 2: 33s-36s.
16. Komissarova, E.V., Tolpygo, S.M., Polyntsev, Iu, V., Krizhevskaia, Iu, V., Shestakov, P.A., Kotov, A.V., Gomazkov, O.A. Biochemical and functional changes during immunization of rats with angiotensin II. Biull Eksp Biol Med 1989, 108(8): 181-5.
17. Beckerhoff, R., Kappeler, M., Vetter, W., Armbruster, H., Siegenthaler, W. Effect of immunization against angiotensin II on blood pressure and on plasma aldosterone in the rabbit. Clin Sci Mol Med 1975, 48(5): 413-20.
18. 1) vaccine ATR12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006, 3(2): 107-114.
19. 2 receptor on hypertension development in young and adult SHR. Physiol Res 1999, 48(4): 259-65.
20. Batenburg, W.W., Garrelds, I.M., Bernasconi, C.C., Juillerat-Jeanneret, L., van Kats, J.P., Saxena, P.R., Danser, A.H. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004, 109(19): 2296-301.
21. Goldblatt, H., Haas, E., Lamform, H. Antirenin in man and animals. Trans Assoc Am Physicians 1951. 64: 122-5.
22. Deodhar, S.D., Haas, E., Goldblatt, H. Induced changes in the antigenicity of renin and the production of antirenin to homologous renin and to human renin. Can Med Assoc J 1964, 90: 236-9.
23. Corvol, P., Devaux, C., Menard, J. Pepstatin, an inhibitor for renin purification by affinity chromatography. FEBS Lett 1973, 34(2): 189-92.
24. Inagami, T., Murakami, K. Pure renin. Isolation from hog kidney and characterization. J Biol Chem 1977, 252(9): 2978-83.
25. Hartroft. P.M. Juxtaglomerular cells. Circ Res 1963, 2: 525-38.
26. Schmid, H.E. Jr., Graham, L.A. Juxtaglomerular cell changes in dogs with antirenin titers. Circ Res 1962, 11: 853-6.
27. Billiau, A., Matthys, P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001, 70(6): 849-60.
28. Ferrer, I., Boada Rovira, M., Sánchez Guerra, M.J., Rey, M.J., Costa-Jussá, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004, 14(1): 11-20.
29. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O. Nouropathology of hurnan Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003, 9(4): 448-52.
30. Orgogazo, J.M., Gilman, S., Dartigues, J.F. et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61(1): 46-54.
31. Lemere, C.A., Maier, M., Peng, Y., Jiang, L., Seabrook, T.J. Novel Abeta immunogens: Is shorter better? Curr Alzheimer Res 2007, 4(4): 427-36.
32. Sielecki, A.R., Hayakawa, K., Fujinaga, M. et al. Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science 1989, 243(4896): 1346-51.
33. Rahuel, V., Rasetti, J., Maibaum, H. et al. Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biel 2000, 7(7): 493-504.
34. Evin, G., Carlson, W.D., Handschumacher, M. et al. Study of the antigenic determinants of human renin. Hypertension 1986, 8(6, Pt. 2): II72-7.
35. Evin, G., Galen, F.X., Carlson. W.D. et al. Characterization of five epitopes of human renin from a computer model. Biochemistry 1988, 27(1): 156-64.
36. Bouhnilk, J., Galen, F.X., Menard, J. et al. Production and characterization of human renin antibodies with region-oriented synthetic peptides. J Biol Chem 1987, 262(6): 2913-8.
37. Fehrentz, J.A., Heitz, A., Seyer. R. et al. Peptides mimicking the flap of human renin: Synthesis, conformation, and antibody recognition. Biochemistry 1988, 27(11): 4071-8.
38. Gardiner, S.M., Auton, T.R., Downham, M.R. et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 2000, 129(6): 1178-82.
39. Jennings, V.M. Review of selected adjuvants used in antibody production. ILAR J 1995, 37(3): 119-25
40. Dyer, M.R., Renner, W.A., Bachmann, M.F. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today 2006, 11 (21-22): 1028-33.
41. Michel, J.B. Renin-angiotensin vaccine: Old story, new project 'efficacy versus safety'. Clin Sci 2004, 107(2): 145-7.
42. Christlieb, A.R., Biber, T.U., Hickler, R.B. Studies on the role of angiotensin in experimental renovascular hypertension: An immunologic approach. J Clin Invest 1969, 48(8): 1506-18.
43. Eide, I. Renovascular hypertension in rats immunized with angiotensin II. Circ Res 1972, 30(2): 149-57.
44. Macdonald, G.J., Louis, W.J., Renzini, V., Boyd, G.W., Peart, W.S. Renal-clip hypertension in rabbits immunized against angiotensin II. Circ Res 1970, 27(2): 197-211.
45. Oates, H.F., Stokes, G.S., Storey, B.G., Glover, R.G., Snow, B.F. Renal hypertension in rats immunized against angiotensin I and angiotensin II. J Exp Med 1974, 139(2): 239-48.
46. Oster, P., Bauknecht, H., Hackenthal, E. Active and passive immunization against angiotensin II in the rat and rabbit. Evidence for a normal regulation of the renin-angiotensin system. Circ Res 1975, 37(5): 607-14.
47. Jegerlehner, A., Tissot, A., Lechner, F. et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20(25-26): 3104-12.
48. Bachmann, M.F., Rohrer, U.H., Kundig, T.M., Burki, K., Hengartner, H., Zinkernagel, R. M. The influence of antigen organization on B cell responsiveness. Science 1993, 262(5138):
49. Mihailova, M., Boos, M., Petrovskis, I. et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 2006, 24(20): 4369-77.
50. Chackerian, B., Rangel, M., Hunter, Z., Peabody, D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 2006, 24(37-39): 6321-31.
51. Chackerian, B., Lowy, D.R., Schiller, J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001, 108(3): 415-23.
52. Ferreira, A.J., Santos, R.A. Cardiovascular actions of angiotiensin-(1-7). Braz J Med Biol Res 2005, 38(4): 499-507.
53. Santos, R.A., Simoes e Silva, A.C., Maric, C. et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003, 100(14): 8258-63.
54. Suzuki, S., Doi, Y., Aoi, W., Kuramochi, M., Hashiba, K. Effect of angiotensin III on blood pressure, renin-angiotensin-aldosterone system in normal and hypertensive subjects. Jpn Heart J 1984, 25: 75-85.
55. Patel, J.M., Martens, J.R., Li, Y.D., Gelband, C.H., Raizada, M.K., Block, E.R. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. Am J Physiol 1998, 275(6, Pt. 1): L1061-8.
56. Vinh, A., Widdop, R.E., Drummond, G.R., Gaspari, T.A. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 2008, 77(1): 178-87.
57. Braszko, J.J., Kupryszewski, G., Witczuk, B., Wisniewski, K, Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 1988, 27(3): 777-83.
58. Braszko, J.J., Kulakowska, A., Winnicka, M.M. Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats. J Physiol Pharmacol 2003, 54(2): 271-81.
59. Kwoon, S.M., Ru, T.F., Guang, X.X. Effects of des-aspartate-angiotensin I on neointima growth and cardiovascular hypertrophy. Regul Pept 2004, 117(3): 213-7.
60. Jankowski, V., Vanholder, R., van der Giet, M. et al. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007, 27(2): 297-302.
61. Strakosch, C.R., Wenzel, B.E., Row, V.V., Volpé, R. Immunology of autoimmune thyroid diseases. N Engl J Med 1982, 307(24): 1499-507.
62. Davies, T.F., Ando, T., Lin, R.Y., Tomer, Y., Latif, R. Thyrotropin receptor-associated diseases: From adenomata to Graves disease. J Clin Invest 2005, 115(8): 1972-83.
63. Ando, T., Latif, R., Daniel, S., Eguchi, K., Davies, T.F. Dissecting linear and conformational epitopes on the native thyrotropin receptor. Endocrinology 2004, 145(11): 5185-93.
64. Morgenthaler, N.G., Ho, S.C., Minich, W.B. et al. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites. J Clin Endocrinol Metab 2007, 92(3): 1058:65.
65. 1 receptor blockade by specific antibody prevented two-kidney, one-clip renal hypertension in the rat. Eur J. Pharmacol 1994, 260(1): 95-8.
66. 1 receptors by specific antibody attenuated hypertension development in young spontaneously hypertensive rats. Physiol Res 1996, 45(6): 475-7.
67. Zhu, F., Liao, Y.H., Li. L.D., Wei, Y.M., Wang, M., Chen, M., Wei, F. Observation of long-term efficacy and safety of an ATR12181 vaccine against hypertension in SHR. Circulation 2006, 114(Suppl. II): 575.
68. Van den Brande, J.M., Braat, H., van den Brink, G.R. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124(7): 1774-85.
69. Dahlöf, B., Sever, P.S., Poulter, RR. et al. Prevention of cardiovascular events with an antihypertensive re en of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005, 366(9489): 895-906.
70. Morgan, T.O., Anerson, A.I., Maclnnis, R.J. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001, 14(3): 241-7.
71. Dikerson, J.E., Hingorani, A.D., Ashby, M.J., Palmer, C.R., Brown, M.J. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353(9169): 2008-13.
72. Xu, S.Z., Zeng, F., Lei, M. et al. Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol 2005, 23(10): 1289-93.
73. Ghochikyan, A., Vasilevko, V., Petrushina, I. et al. Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene. Eur J Immunol 2003, 33(12): 3232-41.
74. Ruiz, P.J., Garren, H., Ruiz, I.U. et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: Modulation of T cell costimulation. J Immunol 1999, 162(6): 3336-41.
75. Hara, H., Monsonego, A., Yuasa, K. et al. Development ofa safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimers Dis 2004, 6(5): 483-8.
76. Kim, H.D., Jin, JJ, Maxwell, J.A., Fukuchi, K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett 2007, 112(1): 30-8.
77. Perham, R.N., Terry, T.D., Willis, A.E., Greenwood, J., di Marzo Veronese, F., Appella, E. Engineering a peptide epitope display system on filamentous bacteriophage. FEMS Microbiol Rev 1995, 17(1-2): 25-31.
78. Willis, A.E., Perham, R.N., Wraith, D. Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene 1993, 128(1): 79-83.
79. Meola, A., Delmastro, P., Monaci, P. et al. Derivation of vaccines from mimotopes. Immunologic properties of human hepatitis B virus surface antigen mimotopes displayed on filamentous phage. J Immunol 1995, 154(7): 3162-72.
80. Frenkel, D., Dori, M., Solomon, B. Generation of anti-beta-amyloid antibodies via phage display technology. Vaccine 2004, 22(19): 2505-8.
81. Shivachandra, S.B., Li, Q., Peachman, K.K. et al. Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 2007, 25(7): 1225-35.
82. Sathaliyawala, T., Rao, M., Maclean, D.M., Birx, D.L., Alving, C.R., Rao, V.B. Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: A novel in vitro approach to construct multicomportent HIV vaccines. J Virol 2006, 80(15): 7688-98.
83. Li, Q., Shivachandra, S.B., Leppla, S.H., Rao, V.B. Bacteriophage T4 capsid: A unique platform for efficient surface assembly of macromolecular complexes. J Mol Biol 2006, 363(2): 577-88.
84. Naz, R.K., Dabir, P. Peptide vaccines against cancer, infectious diseases, and conception. Front Biosci 2007, 12: 1833-44.
85. Agadjanyan, M.G., Ghochikyan, A., Petrushina, I. et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005, 174(3): 1580-6.